Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Inventory (2020 - 2026)

GeneDx Holdings has reported Inventory over the past 7 years, most recently at $12.2 million for Q1 2026.

  • Quarterly Inventory fell 3.32% to $12.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $12.2 million through Mar 2026, down 3.32% year-over-year, with the annual reading at $14.0 million for FY2025, 31.0% up from the prior year.
  • Inventory was $12.2 million for Q1 2026 at GeneDx Holdings, down from $14.0 million in the prior quarter.
  • Over five years, Inventory peaked at $44.2 million in Q3 2022 and troughed at $8.8 million in Q4 2023.
  • The 5-year median for Inventory is $11.9 million (2025), against an average of $16.6 million.
  • Year-over-year, Inventory surged 42.82% in 2022 and then tumbled 78.84% in 2023.
  • A 5-year view of Inventory shows it stood at $13.7 million in 2022, then crashed by 35.77% to $8.8 million in 2023, then grew by 21.34% to $10.6 million in 2024, then skyrocketed by 31.0% to $14.0 million in 2025, then dropped by 12.26% to $12.2 million in 2026.
  • Per Business Quant, the three most recent readings for WGS's Inventory are $12.2 million (Q1 2026), $14.0 million (Q4 2025), and $10.6 million (Q3 2025).